Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(Nausea and vomiting)
38,856 results
  • Diabetic gastroparesis: current challenges and future prospects. [Review]
  • CEClin Exp Gastroenterol 2018; 11:347-363
  • Avalos DJ, Sarosiek I, … McCallum RW
  • Diabetic gastroparesis (DMGP) is a condition of delayed gastric emptying after gastric outlet obstruction has been excluded. Symptoms of nausea, vomiting, early satiety, bloating, and abdominal pain ...
  • [Curative Effect of Aprepitant Preventing CINV]. [Journal Article]
  • ZFZhongguo Fei Ai Za Zhi 2018 Oct 20; 21(10):800-804
  • Guan S, Zhang L, … Liu X
  • CONCLUSIONS: Aprepitant with tropisetron and dexamethasone prevented effectively CNIV for patients receiving Cisplatin chemotherapy. This combination could improve the quality of life and the compliance of patient with chemotherapy.
  • Hepatic Involvement in Systemic Sarcoidosis. [Journal Article]
  • AJAm J Case Rep 2018 Oct 11; 19:1212-1215
  • Ibrahim AM, Bhandari B, … Mamillapalli CK
  • CONCLUSIONS: The majority of patients with hepatic sarcoidosis are usually asymptomatic, with only 5-30% presenting with abdominal pain, jaundice, nausea, vomiting, and hepatosplenomegaly. In rare cases, hepatic sarcoidosis can lead to cholestasis, portal hypertension, cirrhosis, or Budd-Chiari syndrome. Treatment with steroids is the mainstay of therapy; however, in severe cases, patients may require liver transplantation. This case report demonstrates that hepatic sarcoidosis is a serious condition, and if not treated, can lead to portal hypertension and cirrhosis. In patients with sarcoidosis, early detection and longitudinal follow-up is important in preventing overt liver failure.
New Search Next